
AUTHORIZED BY: CPC Quality of Care Committee
ISSUE DATE: June 2002
CATEGORY: ACP Medications
TITLE: **Xylometazoline HCL**

REVISION DATE: Sept 2018
PAGE: 1 of 1

-
- Other Names:**
- Otrivin
- Classifications:**
- Topical Vasoconstrictor
- Pharmacodynamics:**
- Stimulation of Alpha - 1 and 2 receptors in the nasal mucosa, causing constriction of the sub epithelial pre-capillary sphincters, arterioles and venous sinuses
- Onset:**
- Immediate
- Peak:**
- No documentation found
- Duration:**
- Up to 12 hrs
- Indications:**
- Blind nasotracheal intubation; vasoconstriction of the vessels in the nasal passages reduces the risk of epistaxis post ET introduction
- Contraindications:**
- Hypersensitivity
 - Angle closure glaucoma
 - Concurrent therapy with MAO inhibitors
- Precautions:**
- Hypertension
 - Hyperthyroidism
 - Concurrent use of Beta blockers
- Adverse Reactions:**
- May cause local burning, stinging, sneezing, or dryness of mucous membranes
- Drug Interactions:**
- None significant
- Special Considerations:**
- As soon as the need for blind nasotracheal intubation is recognized, pre-medicate the patient with two sprays of Xylometazoline in each nare.
 - The spray bottle is single patient use only
- Preparations:**
- Adult - 0.1% (20 ml bottles)
- References:**
- Ontario Provincial ALS Patient Care Standards (ACP), Version 4.5
 - Compendium of Pharmaceuticals and Specialties 2013
 - 2015 AHA Guidelines : ACLS

NOTE: *The information contained herein does not supersede or negate the MoHLTC Provincial Medical Directives and should only serve as general information about the medication itself. For medication dosages, please refer to the current version of the Ontario Provincial ALS Patient Care Standards.*